70 – Atherosclerosis, Thrombosis, and Vascular Biology

[1]  Robert L Wilensky,et al.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.

[2]  J. Mariani,et al.  Coadministration of atorvastatin prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance in healthy humans. , 2011, Journal of the American College of Cardiology.

[3]  Joseph Lau,et al.  The Vulnerable Atherosclerotic Plaque: Scope of the Literature , 2010, Annals of Internal Medicine.

[4]  A. Hamsten,et al.  Genetics of Atherothrombosis and Thrombophilia , 2010, Current atherosclerosis reports.

[5]  S. Agewall,et al.  Matrix metalloproteinases in atherothrombosis. , 2010, Progress in cardiovascular diseases.

[6]  Paul M Ridker,et al.  Inflammation in atherosclerosis: from pathophysiology to practice. , 2009, Journal of the American College of Cardiology.

[7]  Ian J. Brown,et al.  Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. , 2009, JAMA.

[8]  M. Pencina,et al.  Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. , 2009, JAMA.

[9]  R. Virmani,et al.  Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. , 2009, Journal of the American College of Cardiology.

[10]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[11]  Diederick E Grobbee,et al.  Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. , 2007, JAMA.

[12]  S. Yusuf,et al.  Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials , 2006, The Lancet.

[13]  V. Fuster,et al.  Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. , 2005, Journal of the American College of Cardiology.

[14]  G. Hansson.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[15]  S. Chien,et al.  Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. , 2011, Physiological reviews.